A Phase 1/2 interventional study of HRS-4508+ Capecitabine and HRS-4508+ Trastuzumab in Solid Tumor, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combination with other anti tumor therapy in subjects with solid tumor ; to evaluate HRS-4508 DLT, MTD and RP2D, to evaluate the incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0), to evaluate ORR by researchers based on RECIST v1.1, to evaluate the pharmacokinetic (PK) characteristics of HRS-4508 SHR-1811, Capecitabine.
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HRS-4508+ Capecitabine
Drug: HRS-4508+ Trastuzumab
Drug: HRS-4508+ Trastuzumab+ Pertuzumab
Drug: HRS-4508+ Trastuzumab+ Pertuzumab+ Nab-paclitaxel
Drug: HRS-4508+ Trastuzumab + Nab-paclitaxel
Drug: HRS-4508+ Trastuzumab+ Capecitabine
Drug: Trastuzumab+ Capecitabine
Drug: Trastuzumab+ Pertuzumab
Drug: HRS-4508+SHR-A1811
Drug pages: HRS-4508 · Capecitabine
HRS-4508+ Capecitabine
Drug pages: HRS-4508 · Trastuzumab
HRS-4508+ Trastuzumab
Drug pages: HRS-4508 · Trastuzumab · Pertuzumab
HRS-4508+ Trastuzumab+ Pertuzumab
Drug pages: HRS-4508 · Trastuzumab · Pertuzumab · Albumin-Bound Paclitaxel
HRS-4508+ Trastuzumab+ Pertuzumab+ Nab-paclitaxel
Drug pages: HRS-4508 · Trastuzumab · Albumin-Bound Paclitaxel
HRS-4508+ Trastuzumab + Nab-paclitaxel
Drug pages: HRS-4508 · Trastuzumab · Capecitabine
HRS-4508+ Trastuzumab+ Capecitabine
Drug pages: Trastuzumab · Capecitabine
Trastuzumab+ Capecitabine
Drug pages: Trastuzumab · Pertuzumab
Trastuzumab+ Pertuzumab
Drug pages: HRS-4508 · Trastuzumab rezetecan
HRS-4508+SHR-A1811
HRS4508 DLT
Time frame: 3 weeks
HRS4508 MTD
Time frame: 12 weeks
HRS4508 RP2D
Time frame: 12 weeks
The incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0)
Time frame: 2 years
Objective response rate (ORR)
Time frame: 1 year
Blood concentrations of HRS-4508
Time frame: 15 weeks
Blood concentrations of SHR-A1811
Time frame: 9 weeks
Blood concentrations of Capecitabine
Time frame: 2 weeks
Objective response rate (ORR)
Time frame: 1 year
Best overall efficacy (BOR)
Time frame: 1 year
Duration of response (DoR)
Time frame: 1 year
Progression free survival (PFS)
Time frame: 1 year
Disease control rate (DCR)
Time frame: 1 year
Overall survival (OS)
Time frame: 2 year
The incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0)
Time frame: 2 years
Blood concentrations of Paclitaxel for Injection
Time frame: 6 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: HRS-4508 · Capecitabine · Trastuzumab · Pertuzumab · Albumin-Bound Paclitaxel · Trastuzumab rezetecan
Jiangsu HengRui Medicine Co., Ltd. →